The Role of Bcl-2, CD10 and CD34 Expression in Differentiation between Basal Cell Carcinoma and TrichoepitheliomaReportar como inadecuado

The Role of Bcl-2, CD10 and CD34 Expression in Differentiation between Basal Cell Carcinoma and Trichoepithelioma - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background: Basal cellcarcinoma BCC and trichoepithelioma TE have some similarities clinicallyand histologically. The aim of this work is to evaluate the role of Bcl-2, CD10and CD34 in differentiation between BCC and TE. Methods: Theimmunohistochemical expression of Bcl-2, CD10 and CD34 was evaluated in 20 BCCsand 12 TEs in a retrospective study. The localization of these markers in tumorand stromal cells was determined and comparison between BCC and TE was done.Immunohistochemistry for Bcl-2, CD10 and CD34 was performed on sectionsobtained from formalin-fixed, paraffin-embedded blocks. Bcl-2, CD10 and CD34immunoreactivity in the stromal and-or tumor cells was determined as follows:negative 0; 1+ 10% - 50% positive cells; and 2+ >50% positive cells. Results:In BCC 20 cases, the expression of Bcl-2 in stromal cells showed 0immunoreactivity in 8 cases 40%, 1+ immunoreactivity in 7 cases 35%, and2+ immunoreactivity in 5 cases 25%. Tumoral cells showed diffuse positivityin 20 out of 20 cases 100%, 1+ immunoreactivity in 5 cases 25% and 2+immunoreactivity in 15 cases 75%. On the other hand, the expression of Bcl2in TE, 4 cases showed positive stromal cells out of 12 33.33%, 1+immunoreactivity in 2 cases 16.6% and 2+ immunoreactivity in 2 cases16.6%, and 8 cases showed no immunoreactivity. Tumoral cells showedpositivity in 12 out of 12 cases 100%, 1+ immunoreactivity in 5 cases41.6%, 2+ immunoreactivity in 7 cases 58.3%. In BCC cases, the expressionof CD10 was noted in stromal cells in 8 out of 20 cases 40%, 5 cases showedpositivity in stromal and basaloid cells and 3 cases showed positivity instromal cells only, and 12 cases showed no immunoreactivity 60%. Tumor cellsshowed positivity in 11 cases out of 20 55%, 1+ immunoreactivity in 6 cases30%, 2+ in 5 cases 25%, and 9 cases showed no immunoreactivity 45%. Onthe other hand, the expression of CD10 in TE 7 cases showed positive stromalcells out of 12 58.33%, 1+ immunoreactivity in 5 cases 41.6% and 2+ in2 cases 16.6%, and 5 cases showed no immunoreactivity 41.66%. Tumor cellsshowed positivity in 5 cases out of 12 41.66%, 1+ immunoreactivity in 4cases 33.33% and 2+ in 1 case 8.3%, and 7 cases showed noimmunoreactivity 58.33%. In BCC cases, the expression of CD34 was noted instromal cells in14 cases out of 20 cases 70%, 1+ immunoreactivity in 10cases 50% and 2+ in 4 cases 20%, and 6 cases showed no immunoreactivity 30%.On the other hand, the expression of CD34 in TE, 10 cases showed positivestromal cells out of 12 83.33%, 1+ immunoreactivity in 6 cases 50% and2+ in 4 cases 33.33%, and 2 cases showed no immunoreactivity 16.6%. Tumorcells showed no immunoreactivity for CD 34 in both BCC and trichoepithelioma,100% negative tumor cells. Significant difference of tumor\stromal cellsimmunoreactivity for Bcl-2 and CD34 in both BCC and TE but it was insignificantfor CD10. Conclusion: We conclude that Bcl-2 CD10, CD34 are useful markers inthe differential diagnosis of BCC versus TE.


Basal Cell Carcinoma, Trichoepithelioma, Bcl-2, CD10, CD34

Cite this paper

Raheem, S. , Alsahaer, R. , Tealeb, A. and Rushdy, E. 2014 The Role of Bcl-2, CD10 and CD34 Expression in Differentiation between Basal Cell Carcinoma and Trichoepithelioma. Open Journal of Pathology, 4, 116-124. doi: 10.4236-ojpathology.2014.43018.

Autor: Sayed Abdel Raheem, Rabee Alsahaer, Alsayed Tealeb, Emad Rushdy



Documentos relacionados